Evidence map›Paper›PMID 38432964›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Unresectable Combined Hepatocellular-cholangiocarcinoma Treated with Combination Therapy Consisting of Durvalumab Plus Tremelimumab.

Shinji Unome, Kenji Imai, Takao Miwa, Tatsunori Hanai, Atsushi Suetsugu, Koji Takai, Natsuko Suzui, Tatsuhiko Miyazaki, Masahito Shimizu

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Shinji UnomeDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Japan.
Kenji ImaiDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Japan.
Takao MiwaDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Japan.
Tatsunori HanaiDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Japan.
Atsushi SuetsuguDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Japan.
Koji TakaiDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Japan.
Natsuko SuzuiDepartment of Pathology, Gifu University, Japan.
Tatsuhiko MiyazakiDepartment of Pathology, Gifu University, Japan.
Masahito ShimizuDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Japan.
Gifu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combined hepatocellular cholangiocarcinoma is a rare and challenging primary liver malignancy that lacks any established standard treatments for unresectable cases. We herein present the first known case of a 49-year-old woman diagnosed with unresectable combined hepatocellular-cholangiocarcinoma, who underwent novel chemotherapy involving durvalumab plus tremelimumab combination therapy. The treatment was temporarily discontinued owing to immune-related adverse events, such as rash, and the patient was subsequently managed with systemic steroid therapy; however, the disease progressed after two courses of this treatment. Further studies are needed to validate the efficacy and safety of immune checkpoint inhibitors such as durvalumab and tremelimumab for the treatment of unresectable combined hepatocellular cholangiocarcinoma.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBile Duct NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaLiver NeoplasmsFemaleHumansMiddle AgedTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, Humanizeddurvalumabtremelimumabcombined hepatocellular-cholangiocarcinomadurvalumabimmune check-point inhibitortremelimumab

Identifiers

PMID38432964
PMCPMC11518598
OpenAlexW4392443012

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.